EXCITING NEWS...REACT and ITOG to Merge 2019
The Board of Directors would like to thank you for supporting REACT, the inspiration of my dear daughter Michelle. Her passion and initiative to help others afflicted with medullary thyroid carcinoma (MTC) by creating REACT exemplifies her heart and selflessness.
Since Michelle’s passing, my daughter Kimberly and I have done our best to continue the good work of REACT, along with the wonderful assistance of many volunteers. We have raised over $750,000 over the years to invest in research to find a cure for thyroid cancer.
Kimberly and I have decided that the best way to keep Michelle’s legacy alive and expand the great work of REACT is to merge with the International Thyroid Oncology Group, or ITOG. ITOG is the preeminent organization that brings together the leaders in the field to develop better treatments for all types of thyroid cancer, including MTC. ITOG was inspired by another MTC patient, who like Michelle, turned her anxiety and feelings of hopelessness into action. The merger with ITOG should be effective January 1, 2019.
The REACT name and mission will be preserved with ITOG. You can continue to support the work of REACT through your existing mechanisms. You will also see greater involvement from our friends at ITOG.
Kimberly and I are confident that ITOG has the best team to nurture and execute the mission of REACT. I know Michelle would be pleased as well.
Very truly yours,
REACT Thyroid Foundation, a 501(c)(3) public charity, is dedicated to creating awareness for thyroid cancer and raising funds to support research for new treatment options and ultimately find a cure.
Research - Raise funds to support the research of top doctors, scientists and institutions
Education - Increase early detection through "Neck Checks" at home and during routine doctor appointments
Action - Encourage those touched by thyroid cancer to join this important crusade
Cancer - Grow support for thyroid cancer which currently lacks the funding other cancer research receives due to its low incidence rate
Thyroid - Reduce the number of thyroid cancer cases which the American Cancer Society estimates will be 56,000 new cases in the U.S. in 2012
The REACT Thyroid Foundation was founded in August 2011 by a courageous young woman, Michelle LeBeau. In 2009, at the age of 30, Michelle was diagnosed with a rare and incurable form of thyroid cancer called medullary thyroid carcinoma. At the time of diagnosis, the cancer had spread to her lungs and was classified as stage 4C. There is no known cure for medullary thyroid carcinoma, or any form of advanced-stage thyroid cancer, and it is not responsive to traditional chemotherapy.